Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
AssigneeNanjing IASO Biotechnology Co., Ltd.
InventorsYongkun Yang, Guang Hu, Taochao Tan, Zhenyu Dai, Panpan Niu, Guangrong Meng, Wei Cheng, Xiangyin Jia, Jialu Mo, Wen Wang, Bailu Xie, Junfeng Yang, Fei Zhou
Life of this patent
Estimating the term…
Abstract
Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.
Claims18
A bispecific chimeric antigen receptor targeting CD19 and CD22, comprising an extracellular antigen-binding domain, the extracellular antigen-binding domain comprises a heavy chain variable region and a light chain variable region of an anti-CD19 antibody and a heavy chain variable region and a light chain variable region of an anti-CD22 antibody, wherein
- the amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-CD19 antibody are selected from any of the following combinations:
- the heavy chain variable region sequence comprising SEQ ID NO:
- 2 and the light chain variable region sequence comprising SEQ ID NO:
- 4;
- and
- the heavy chain variable region sequence comprising SEQ ID NO:
- 8 and the light chain variable region sequence comprising SEQ ID NO:
- 6, and
- the amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-CD22 antibody are selected from any of the following combinations:
- the heavy chain variable region sequence comprising SEQ ID NO:
- 10 and the light chain variable region sequence comprising SEQ ID NO:
- 12;
- and
- the heavy chain variable region sequence comprising SEQ ID NO:
- 14 and the light chain variable region sequence comprising SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.